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ay that despite a stmg 
in health care, the re- 
s therefore appropriate 
that the medical ssion examine the impact of develop- 
w therapeutic modalities on the pra 
uch analyses, carefully ~o~d~c~ed, cou 
potentially have an impact on the COSI of medical care 
without dim~~~sb~~g the effectiveness of that care. 
To this end, in 1980 the American College of Cardiology 
and tile Americar; W stablished the Task 
Force on Assessment 
vascular Proc,edures with the following charge: 
The task force of the herican College of Cardiology and the 
American Heart Association shall develop guidelines re- 
lating to the role of new therapeutic approaches and of 
specific noninvasive and invasive procedures in the diag- 
nosis and management af cardiovascular disease. 
The task force shall address, when appropriate, the contri- 
bution, uniqueness, sensitivity, specificity, indications, 
contraindications, and cost-effectiveness of such diagnos- 
tic procedures and therapeutic modalities. 
The task force shall emphasize the role and values of the 
guidelines as an educatiocsl remme. 
The task force shall include a chair and six members, three 
representatives from the American Heart Association and 
three reprczeate’tives from the 14tnerican College of car- 
-: Grace konan, Assistant Director. Special Projects, 
American College of Cardiology, 911 I Old Georgetown Road, Bethesda, 
Maryland 20814-1699. 
“Guidelines for Percutaneous Tmnsluminal Coronq Angiopiasty” was 
approved by the American Heart Association Steering Committee on June 16, 
1993, and by the American Cokge of Cardiology Board of Trustees on June 
30, 1993. 
Q1993 by the American Caltege of Cardiology and American Heart Association 
diology. The task force may select ad hoc members as 
of t 
responsible individuals of the &vo 
ceived final approval in June 1993. 
tion. 
The American College of ~ardio~o~~~e~~~ 
ciation Task Force on Assessment of Diagnost 
apeutic Cardiovascular Procedures was formed to gather 
information and make recommendations about appropriate 
use of technology in the diagnosis and treatment of patients 
with cardiovascular disease. Coronary angioplasty i.s one 
such important technique. We m currently witnessing an 
extraordinary expansion of the use of coronary a@oplasty 
as 811 alteritative mean 
ization. An estimated 
performed in the Unite 
increase over the past decade (1). Such growth is attributable 
not only to demonstrated cSinica1 benefit but also to conth- 
ing technical advances that have led to improved techhues 
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and higher success rates over time. There was some con- 
comitant broadening of the indications for both coronary 
a&ography and angioplasty, which led the task force to 
promulgate guidelines for coronary angiography in 1987 (2) 
and guidelines for percutaneous tranSluminal COrOnNY an- 
giOp]atY @WA) in 1988 (3). In view of the continuing 
advances and expanding role of interventional c rdiology in
clinical practice today, it was recommended that this com- 
mittee review current indications and procedures governing 
the performance of angioplasty in the United States and 
determine whether any alterations in the previously pub- 
lished guidelines are warranted. Such a review was antici- 
pated and recommended in the original committee r port (3). 
This document presents he summary opinion of the recon- 
vened committee with its newly constituted membership. 
These recommendations were shaped over the course of 
9 months’ deliberation a d reflect much thoughtful discus- 
sion and broad consultation, aswell as a detailed review of 
the world literature. The committee proceeded on the 
premise that angioplasty is an effective means of achieving 
myocardial revascularization andits appropriate use is to be 
broadly encouraged. At the same time, the committee is
mindful of the many forces that can affect the performance of 
any specilic procedure and recognizes the potential for a 
variety of inappropriate and expedient considerations to 
influence the performance of angioplasty in this country. 
Accordingly, the committee offers these recommendations 
with a heightened awareness of the need for the cardiology 
community atlarge, and institutional programs specifically, 
to police themselves in the use of coronary angioplasty. 
The technique of angioplasty is in evolution and the 
long-term results are not yet fully elucidated; therefore, ven 
these revised recommendations arelikely to change over 
subsequent years. Because multiple variables must be 
weighed in selecting balloon angioplasty reatment, this 
report is not intended to provide strict indications or con- 
traindications for the procedure. Relevant considerations 
include occupational needs, the family setting, associated 
illnesses, and lifestyle preferences. Rather, the report is 
intended to provide a statement of general consensus that 
may be helpful to the practitioner aswell as to health care 
administrators and other professionals interested in the 
delivery of medical care. The American College of Cardiol- 
ogy and the American Heart Association recognize that he 
ultimate judgment regarding the appropriateness of any 
specific procedure is the responsibility of the physician 
caring for the patient. The guidelines should not be consid- 
ered all-inclusive orexclusive of other methods that may be 
available for the care of the individual pdient. The commit- 
tee will not offer detailed recommendations about he spe- 
cific remrces required to perform coronary angioplasty or 
to train those peTforming the procedure. It is essential that 
physicians performing angioplasty and related procedures 
are adequately trained, that facilities and equipment used are 
capable of obtaining the necessary radiographic information, 
and that he safety record of the l$boratory is acceptable. 
This report includes ome general considerations that 
provide abrief review of the growth and develop 
procedure, identification f contraindications to its use, and 
a statement acknowledging general risks associated with 
angioplasty. A brief discussion of considerations unique to 
angioplasty follows with an enumeration f those factors 
currently recognized asinfluencing the outcome, the re 
ment for surgical backup, performance of angioplasty atthe 
time of initial catheterization, management of the patient 
after angioplasty, he problems ofrestenosis and incomplete 
n, the need for perio 
t~t~tio~al mortality 
guidelines for the ap 
angioplasty are presented; these were dev 
to anatomic (single versus multivessel 
(asymptomatic versus ymptomatic 
ical (presence orabsence of inducible ischemia) consider- 
ations. The indications derived from consensus for angio- 
plasty are judged to be either Class I, II, or III (defined in 
“Indications for Angioplasty”), based primarily on multifac- 
torial risk assessment weighed against expected outcome, 
judgments offeasibility, appropriateness to the clinical set- 
ting, and overall efficacy viewed in t e light of current 
knowledge and technology. 
Background 
Symptomatic coronary artery disease ispresent in more 
than 6 million people in the United States. Despite the 
availability ofeffective medical therapy, a significant propor- 
tion of patients are candidates for a revascularization proce- 
dure because ofunacceptable symptoms orpotentially ife- 
threatening lesions. An estimated 3041 OOQ coronary artery 
bypass operations and 300 Ooo coronary angioplasty proce- 
dures were performed in1990 (1). Although coronary angio- 
plasty is still performed most often in patients with single- 
vessel coronary diseases increasing numbers ofpatients with 
multivessel disease and those who have undergone surgical 
bypass are also being treated. Coronary bypass urgery is 
used most often to treat multivessel coronary disease, with a 
majority of patients receiving three or more bypass grafts. 
Use of tile mternal mammary artery as a conduit has risen 
dramaticrtly in recent years, from less than 4% of the total 
number of procedures (an estimated 6000) in 1983 to more 
than 60% of all operations in 1990 (1). The leading indication 
for surgery continues to be relief of angina, an approach 
supported by findings of randomized trials, that have shown 
that, compared with medical therapy, surgical revasculariza- 
tion significantly reduces symptoms and improves quality of 
life (4). At the same time there has been an expansion ofthe 
patients for whom it is recognized that bypass surgery 
improves survival. This improvement i  survival (5-12) has 
been established in patients with left main coronary disease 
(5), certain patients with three-vessel disease (6-8), some 
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patients with two-vessel disease w
live in ~~~~vja~~~g angina in 
have not yet been trials corn 
surgery. 
Coronary angioplasty +5ras first intmhxd by Andreas 
3) as an alternative form of revascu 
ring the early years of its application Gmewtzig 
used angioplasty predominantly to treat patients 
with discrete proximal no~c~~c~fied subtotal occlusive le- 
ingle coronary artery. In subsequent years the 
as been used successfully in patients with multi- 
vessel disease, multiple su 
certain complete occIusions, partial occlusion of saphenous 
vein or internal mammary artery grafts, or recent otal 
thrombotic occlusions associated with acute myocardial 
in ction. 
y 1980 Gruentzig bad performed t e procedure on I69 
patients, 40% of whom had multivessel 
-year follow-UP of those patients howed 
rm benefit, with 89.5% of the patients survrv- 
ing and 75% remaining asy~~t~~~t~~. Ten-year survival in 
patients with single-vessel disease exceeded that in 
patients with multivessel disease (8 epeat angioplasty 
was required by 31% and coronary bypass urgery by 31% 
(14) Five-year survival in patients reated at Emory Univer- 
sity in 1981, most of whom had single-vessel disease, was 
97% (15) and at 10 years was 92%. Th 
Lung, and Blood Institute stablished a 
1979 to help evaluate the technique. Thl 
3079 patients were entered into the vol 
numerous analyses from this data ban 
the effectiveness and safety of angkpiasty (16). Because 
technical dvances resulted in improved success rates and 
expanded application, a new registry was opened by the 
NHLBI[ in 1985 to evaluate more recent rends In airgio- 
plasty. Sixteen centers agreed to voluntarily collect data on 
an additional 2500 patients. The primary chnical success rate 
increased from 61% in the initial cohort o 78% (C7). Despite 
a change in complexity, with half of the cases in the second 
registry having multivessel disease, the rate of nonfatal 
myocardial nfarction decreased from 4.9% to 4.3% and that 
of emergency oronary artery surgery from 5.8% to 3.4%; 
the mortality rate remained unchanged (1.2% and 1.0%). 
Five-year follow-up of the data from the second registry 
indicates an overall survival rate of 90% (18). 
Investigators in a recently completed trid, Angiopiasty 
Compared to Medical Therapy (19), compared angioplasty 
with medical therapy in patients with single-vessel disease. 
Although improved symptoms and a modest increase in 
hivessel disease has 
rate. The 5-year survival for patients with sin 
with multivessel disease (53% having double-vessel disease 
g triple-vessel disease), the 5-year overall 
t-free survival, defined as free- 
-wave infarction, and coronary bypass 
surgery, was 74% (23). 
Two aspects of balloon angioplasty ave motivated car- 
ts to seek ahernative methods of improving 
obstructed arteries: the acute corn 
ing from the angioplasty 
of late restenosis Mowi 
tomy, laser angioplasty 
results in certain anat 
e occurrence 
an approved new inte~ention~ device, itis to be noted that 
these devices have been approved only for specik indica- 
tions that are more restrictive than those for balloon angio- 
plasty. These guidelines are based principally on experience 
with balloon angioplasty, and throughout this document the 
;<rm “angioplasty” will be used to describe the procedure of
endovascuiar enlargement of he coronary lumen by a bal- 
loon or other device- 
Coronary angioplasty and coronary bypass 
both mtended to improve myocardial b ood 
palliative rather than curative and should be seen as com- 
plementary ather than competitive procedures. Both are 
associated with potential risks, including stroke, myocardial 
injury, and death. 
The major advantage of coronary angioplasty is its rela- 
tive ease of use, avoiding eneral nesthesia, thoracotomy, 
extracorporeal circulation, mechanical ventilation, and pro- 
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longed convalescence. R peat angioplasty can be performed 
more easily than repeat bypass urgery and revasculariza- 
tion can be achieved more quickly in emergency situations. 
The disadvantages of angioplasty are high early restenosis 
rates and the inability to relieve many stenoses because of
the nature and extent of the coronary lesion. 
Coronary bypass urgery has the advantages of greater 
durability (grafl patency rates exceeding 90% at 10 years 
with arterial conduits) and more complete r vascularization 
irrespective of the morphology of the obstructing atheroscle- 
rotic lesion. 
Generally speaking, the greater the extent of coronary 
atherosclerosis and its diffuseness through the vessel wak 
the more compelling the choice of coronary artery bypass 
surgery, particularly if left ventricular function is depressed. 
Patients with lesser extent of disease and localized lesions 
are good candidates for endovascular approaches. The use 
of either technique assumes the presence ofclinical indica- 
tions such as failure of medical treatment tocontrol symp- 
toms or a potential survival benefit. 
The use of the two technologies in terms of patient 
selection and comparisons of outcome await he completion 
of several ongoing randomized clinical trials (26) (the Bypass 
Angioplasty Revascularization Investigation, the Coronary 
Angioplasty Versus 3ypass Revascularization Investigation, 
the Emory Angioplasty Surgery Trial, the German Angio- 
plasty Bypass Investigation, and Randomized Intervention 
Treatment ofAngina) (27) in which the two treatments are 
compared in patients eligible for both techniques. Changing 
technology, institutional nd operator experience, and pa- 
tient preference will continue to influence choice of treat- 
ment. 
The increasing use of angioplasty in suitable patients has 
materially affected the indications for the coronary bypass 
operation. This has resulted in a change in the case mix of 
patients undergoing bypass urgery in recent years: they are 
generally older, have diffuse, extensive coronary disease, 
often with impaired left ventricular function, and are higher- 
risk patients than formerly (28,29). There is also a recog- 
nized paucity of proper isk-adjusted comparisons between 
coronary artery bypass urgery, PTCA, and medical treat- 
ment. Based on data available in 1989, Wang et al. (30) 
constructed a decision ana!yrir: {node1 that addresses the 
question of when myocardial revascularization is i dicated 
for chronic stable angina. The model considers angioplasty 
in addition to bypass surgery and medical therapy and 
SUPPOI% the recommendation that revascularization is ot 
indicated unless evere symptoms, other markers of sub- 
stantial ischemia, or severe multivessel disease are present. 
The analysis also suggests hat angioplasty may be prefera- 
ble to bypass urgery in patients with one- and two-vessel 
disease. In a recent nonrandomized study of consecutive 
patients reated with PTCA or coronary artery bypass graft 
surgery (CABG) for multivessel disease and left ventricular 
dysfunction, in-hospital mortality rates were comparable 
(5% for CABG and 3% for PTCA) (31). Although stroke was 
more common in CABG patients (7% 
= .Ol), there was a trend toward impr 
kr patients who had undergone bypass grafting 
with those who had undergone PTCA (75% and 
.09). Age and incomplete r vascularization, but n 
of revascularizatioa, were found upon multivariate analysis 
to correlate with late mortality. For a more detailed compar- 
ison of CABG with PTCA, the reader is referred to the 
ACClANA guidelines and indications for coronary artery 
bypass urgery (12). 
In general, the contraindications to angioplasty include all 
of the relative contraindications e umerated forthe perfor- 
mance of coronary angiography as outlined in the guidelines 
of an earlier ACUAHA report (2). Before undergoing angio- 
plasty, it is imperative that he patient clearly understand the 
procedure, its potential complications, and the alternatives 
of medical therapy or bypass surgery and have a truly 
informed understanding of the risk-benefit ratio. The impor- 
tance of a relative contraindication t  angioplasty wiII vary 
with the symptomatic state as well as the general medical 
condition of the individual patient. Certain risks may be 
appropriate in severely symptomatic individuals who, for 
example, are not candidates for bypass urgery, whereas 
these risks would be inadvisable for an asymptomatic or 
mildly symptomatic individual. The currently accepied con- 
traindications to the performance of elective coronary angio- 
plasty are the following. 
There is no significant obstructing lesion.* 
There is a significant obstruction (~40%) in the left 
main coronary artery and this main segment is not 
protected by at least one nonobstructed bypass graft 
to the left anterior descending or left circumflex 
artery. 
There is no formal cardiac surgical program wi& 
the institution. 
tive co&raindicatiom 
A coagulopathy is present: conditions associated 
with bleeding abnormalities or hypercoagulable 
states may be associated, respectively, with unac- 
ceptable risks of serious bleeding or thrombotic 
occlusion of a recently dilated vessel. 
The patient has diffusely diseased saphenous vein 
grafts without afocal dilatable sion. 
The patient has diffusely diseased native coronary 
arteries with distal vessels uitable for bypass graft- 
ing. 
*For the purpose f this report, a significant stenosis is defmed as one that 
results in a ~50% reduction i coronary diameter asdetermined bycaliper 
method. 
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resdt in a very low 
on is a ~order~~~e ste- 
t~vcssel disease who are 
undergoing direct angioplasty f0r acute ~yoca~d~al 
infarction. 
itim to these gene ly accepted relative contrai 
dications, there are other isks that caase clinicians to have 
considerable r servations about the ri~~-be~e~t ratio of 
angioplasty. These risks include those 0 
closure, those associatted with emergency 
compared with elective surgery, as well as 
osis. risks are viewed as 
their ate weight should ul 
a specific procedure should or s 
Patients with cfironic renal failure may have increas 
morbidity following coronary a~~o~lasty due to contra 
induced increased renal failure and s~bseq~eot prolong 
hospitalization. ough coronary a~g~o~lasty can be per- 
fortned success in patients on dialysis, the restenosis 
rate has been high (81% in one report) and the long-ter 
outcome has been unfavorable (32). Whether the long-term 
results of patients undergoing renal transplantation arebet- 
ter if coronary angioplasty is performed before or after the 
procedure is unresolved. 
issks Associated 
Because coronary angioplasty requires v~s~a~~zat~o~ of 
the coronary anatomy as well as systemic arterial and 
venous access, patients undergoing the pr 
for the same co~~~~cat~o~s associated 
disc catheterization (2). 
Despite major improvements in angio 
and operator ski!!, abrupt vessel cIosure 
cause of morbidity and mortality, occurring in 3% to 8% of 
procedttres, depending on the definition used (33-39). Coro- 
nary artery dissection, with or without hrombus, is the 
major cause of abrupt vessel closure. Although coronary 
artery spasm appears occasionally to be a contributing factor 
(40), in a number of studies hypotension during or immedi- 
ately after an angioplasty procedure preceded abrupt vessel 
closure (36,41), with a lack of adequate perfusion pressure 
presumably contributing tothe abrupt closure. Intro-aortic 
balloon pumping (42) and vasopressors may restore coro- 
nary artery pcrkrsion pressure. ~tho~gb successful resolu- 
tion of abrup; vessel closure has been accom~~shed with 
percutaneous techniques in as many as two thirds of patients 
(37), the condition is associated with a substantial mortality 
rate (4% to IO%+ and 20% to 30% of patients require 
, advanced age of the 
coronary zngioplasty. 
sary in these patients devices have been 
(52]~. The most experie intra-aortic bakon pump 
co~~te~~lsatio~~ his t has been used with rela- 
tively low rates of morb mortality (53). Emergency 
cardio~ulmona~ support has been used in some centers but 
has the disadvantage of an increased number of associated 
comphcations (54,55). In addition, although the systemic 
circula;ion issupported by this method, coronary pe 
is not provided uring hemodyna~c collapse, and cardio- 
pulmonary support isnot cardioprotective against global and 
regional myocardial dysfunction (56). The indications for 
cadiopulmonary support oeed further clarification, and at 
present the technique should not be used to extend the use of 
coronary angioplasty for higher-risk patients. 
Surgical backup, aseritce that was tho~gbt tobe essen- 
ti$ daring the developmental stages of angiqlas?y, is stiE 
provided in one form or another in most cases of ekctive 
PTCA. 
At present, 2% to 5% of patients undergoing PEA wiU 
2038 RYAN ET AL. 
ACCfAHA TASK FORCE REPORT 
JACC Vol. 221 No. 7 
December 1993:2033-54 
sustain damage (dissection, intimal disruption, Perforation, 
or embolization) to the coronary arteries, requiring emer- 
gency surgical intervention. Emergency coronary artery 
bypass grafting under these circumstances can be done 
effectively but with an operative mortality higher than that 
encountered in comparable patients managed with primary 
elective surgery (I&29,57). Many of these patients have one- 
or two-vessel disease and would be uncomplicated surgical 
patients under elective circumstances. The perioperative 
myocardial. infarction rate remains high, however, and the 
opportunity ouse arteria! conduits i reduced. The mortal- 
?y and myocardial infarction rates following emergency 
surgery for failed PICA increase with the extent of coronary 
disease, the occurrence of cardiac arrest, hemodynamic 
instability, and the need for cardiopulmonary resuscitation, 
which is often required in these circumstances. Also con- 
to the increased mortality and morbidity rates of 
emergency b pass urgery for failed angioplasty are all the 
factors that prolong the time to surgical reperfusion. These 
factors come into play in patients who have had prior heart 
surgery, those in whom conduit material is lacking, and 
especially in those for whom the decision to proceed with 
~“;$rGri+:’ a ‘-.Wr” ~ wgkai revascularization is delayed. Although 
no prospective studies have been done to indicate which 
patients experiencing failed angioplasty should have emer- 
gency surgical revascularization, it is assumed that most 
patients will benefit from an attempt at surgically restoring 
myocardial blood flow under these circumstances. The indi- 
cations for emergency CABG following failed IWA should 
follow the guidelines outlined in the ACClAHA task force 
report (12). 
Because of the variation in institutional practices of 
cardiology and cardiac surgery, there is no standard surgical 
backup for angioplasty. Surgical backup varies from infor- 
mal arrangements in which emergencies are managed with- 
out prior planning or preparation to formal standby in which 
an operating room is kept open and an entire surgical team is 
immediately available. However, there is concern that the 
universal requirement that angiopbsty be done only in 
hospitals having cardiac surgical capability isleading to the 
proliferation i  the United States of small-volume cardiac 
surgical programs whose major ole is to provide surgical 
backup for angioplasty . 
Data from centers in Canada nd Europe, where surgical 
programs are limited in number, suggest that elective angio- 
plasty can be performed inhospitals without cardiac surgical 
capability with results comparable to those of centers having 
this capability (58-60). It must be acknowledged, however, 
that with more than 900 surgicaVangioplasty units available 
in the United States, the relative lack of surgical facilities in 
Canada nd abroad oes not pertain here. This gives rise to 
the current opinion in this country that to do elective 
angioplasty without surgical backup exposes both the patient 
and Physician to unnecessary risk and should not be done 
routinely (61). 
Formal suQ$C~ standby that necessitates he expenditure 
of enormous resources toprovide an operating room, equig- 
ment, supplies, and highly trained personnel for a Procedure 
that will be used Iess than 5% of tbe time is both expensive 
and inefficient (62). For this reason, surgical backu 
angioplasty is increasingly provided on a more i 
basis. Better selection of Patients and lesions for angio- 
piasty, better catheter systems, improved technical compe- 
tence, more stringent credentialing, case-load requirements 
for those who perform angioplasty, and various “bail-out” 
techniques have made formal surgical standby less neces- 
sary than during the developmental phas 
gioplasty (63,64). The sine qua non for opt 
goad communication among cardiologist, 
cardiac anesthesiologist, and support personnel in the car- 
diac catheterization laboratory and operating room. 
The current national standard ofaccepted medical prac- 
tice for coronary angioplasty requires that an experienced 
cardiovascular surgical team be available within the institu- 
tion* to perform emergency oronary bypass urgery should 
the clinical need arise (3,121. Although technical dvances, 
operator experience, and alternative r perfusion strategies 
have somewhat lessened the rate of emergency bypass 
surgery after failed elective angioplasty, surgical backup has 
proved life-saving and has effectively reduced subsequent 
morbidity such that it is deemed mandatory b  this commit- 
tee for all elective angioplasty procedures. After reviewing 
all the available vidence, being aware of the experience 
abroad where on-site surgical backup is not a requirement 
and mindful of the economic pressures toalter this standar 
of practice, this subcommittee affirms its conviction that 
such a policy is in the best interest of the patient. 
For patients in whom angioplasty is clearly the most 
appropriate method of therapy, formal surgical consultation 
is not deemed necessary and will likely increase costs and 
may result in longer hospitalizations. For patients with 
high-risk features or in whom the extent of the disease may 
indicate tha: bypass urgery is an equally or more effective 
method of therapy, a surgical consultation is advisable. This 
is especially true for patients for whom a high rate of 
complications of either angioplasty orbypass urgery may 
be anticipated. 
The exact arrangement for surgical backup will vary from 
one institution to another, depending on such obvious fac- 
tors as the number of operating rooms available for cardiac 
surgery and the number of surgeons, perfusionists, nurses, 
and other personnel on hand. The essential requirement is 
the capacity to provide surgery promPtly when angioplasty 
fails; otherwise, optimal patient care may be seriously com- 
promised. 
The requirement foron-site surgical backup for patients 
*“Within the institution” is generally intended to mean within the same 
hospital. When two hospitals are physically connected such that emergency 
transpofl by stretcher or gurney can be achieved rapidly and efFectiveif. Ihe 
transport ofpatients between the two hospitals for emergency cardiac surgical 
services would not be considered off site. 
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0). For this re%son, 
widespread vailability ofa 
acute infarction would pot 
some patients, ~a~~cu~~~y thosewith absolute contraindi- 
cations to t~ombo~ytic herapy. At the same time, it must 
also be recognized that a~~op~asty carried out during the 
early hours of acute myocardial i~f~ct~o~ is frcq~e~t~y 
ult reqlmires ven more skiil a 
ne oplasty petiormed in stable 
the need for experienced operators int 
the only concefn. It s 
ence of the laboratory 
broad range of cathet 
required for optimal results 
Limiting angioplasty ia acute 
ratories with in-house surgic up ensures that these 
procedures are performed inlaboratories that have ongoing 
and regular experience with a::ngioplasty. In point of fact, 
surgical backup has become a surrogate for experienced, 
well-equipped laboratories. This consideration is far more 
important than the presence ofsurgical backup, especially in
light of the recognized dilYerence in the risk-benefit ratio of 
angioplasty performed inthe setting of an acute myocardial 
infarction. 
Data from observational studies indicate that certain 
high-risk patients with acute myocardial infarction, such as 
those developing hypotension rcongestive heart failure or 
those in frank cardiogenic shock, benefit Tom emerge 
angioplasty of the infarct-related artery (72,731. 
tients are considered tobe in Class IHa in the ACCI 
force guidelines for the early management of patients with 
acute myocardia! infarction (74). Thus, there may be patients 
at very high risk suffering acute myocardial ~~arctio~~ who
may or may not be suitable for thrombolytic therapy, in 
whom emergency angioplasty without on-site surgical 
backup is acceptable treatment if the aMi@ to transfix the 
eption for the need of on-site sugic 
styIsurgical centers) in the manage 
s with unstable 
suggest that immediate angioplasty in patients with unstable 
angina may increase t risk of comp~cat~o~s (75,761. 
There are those o argue that patients who refuse 
bypass urgery as a therapeutic option or those who are 
considered nonsurgical ndidates could reasonably undergo 
angioplasty atinstitutions without on-site sur&d bat 
The committee views such reasoning as specious and be- 
tieves that truly informed judgments of this kind are best 
made when such patients are in institutions with experienced 
cardiovascular surgical teams, so that options can be 
adequately considered. 
Need for ~~~~~~~~~~~~~ view 
A rigorous mechanism valid peer review musl be 
established and ongoing ipl each instiMon performing car- 
omy angioplusty because 1)angioplasty is an i~te~e~t~o~~ 
procedure associated with known risks of serious complica- 
tions, including death, 2) iI is a therapeutic mod 
efficacy has a recognized association with operator skill and 
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Table 1. Recommendations for Clinical Competence in Percutaneous Transluminal Coronary 
Angiography: Minimum Recommended Number ofCases Per Year 
Society for
Bethesda Cardiac 
Conference Angiography ACCIAHA ACPlACClAHA ACGAHA 
17 (79) (781 (3) (771 (1993) 
Training 
Total number of cases 125 125 125 125 125 
Cases as primary operator 75 75 75 75 75 
PhWtiCiUg 
Number of cases per year . . . 50 52 75 75 
to maintain competency 
experience, and 3) in certain instances, the procedure can be 
viewed as a remunerative undertaking performed by the 
same physician who initiates and interprets he diagnostic 
studies leading to the procedure itself. 
Although institutional review can take many forms and 
will vary according to such factors as the size of institutions 
and departments, he number of staff, and the volume of 
procedures, there are basic requirements fora meaningful 
review, At a minimum, there must be the opportunity for 
physicians, including those who do not perform PTCAs but 
are knowledgeable about he procedure, toreview the over- 
all results of the program on a regular basis. Specific 
attention should be paid to the general indications, the 
success and failure rates of individual operators, the number 
of procedures performed per operator, their ates of compli- 
cations (including emergency surgical procedures), and mor- 
tality rates. The review process hould examine and docu- 
ment he quality and accuracy of cinearteriographic studies 
and the appropriateness of indications, and it should include 
discussion ofcontraindications. An active database for qual- 
ity assessment issues hould be established. 
The committee also identifies a critical need for the 
institutional review process to ascertain that individual op 
erators meet national credentialing standards a promulgated 
by the ACPIACCIAHA Task Force on Clinical Privileges in
Cardiology inits statement onclinical competence in PTCA 
(77) (Table 1). Documentation f training in a structured 
fellowship program during which a minimum of 125 coronary 
angioplasty procedures, including 75 performed with the 
trainee as the primary operator, is required to ascertain 
competence in the procedure (77-79). A major concern isthe 
reality that a majority of operators fail to meet he require- 
ments for maintenance of competence, which is a minimum 
of 75 PITA procedures performed per year as the primary 
operator (3,77). While acknowledging that minimums do not 
guarantee competence, the committee strongly endorses the 
recommendations f the ACPlACClAHA Task Force on 
Clinical Privileges in Cardiology and believes the prolifera- 
tion of small-volume operators should be curtailed by appro- 
priate institutionai review. To this end, the committee r t- 
ommends that angioplasty operators who fail to meet hese 
requirements be required to discontinue the performance of 
the procedure. 
Maintenance of competence is ~~po~a~t not only for 
physicians performing PTCA but also for the i~st~t~t~o~ 
offering this service, A significant number of cases per 
institution-at least 200 P’KA procedures annually-is es- 
sential for the maintenance of quality and safe care (SO). 
Exceptions to this minimum ust be based on documenta- 
tion of high-quality performance of appropriate procedures 
within the institution (77). 
Institutions with medical or surgical groups, or both, that 
cannot adequately meet he obligation ofappropriate insti- 
tutional review should undertake r gional review with coop- 
erating institutions or terminate their 
plasty. 
A successful angioplasty procedure isdefined as one in 
which a 220% change in luminal diameter is achieved, with 
the final-diameter stenosis ~50% and without the occurrence 
of death, acute myocardial infarction, or the need for emer- 
gency bypass operation during hospitalization. While thIr is 
the technically accepted definition and the one used for the 
NHLBI registry, it is conventional practice to reduce most 
lesions to a final-diameter stenosis of <30%. Atherosclerotic 
coronary stenoses are considered significant if hey have the 
potential to impair coronary blood flow under physiological 
circumstances. The visual assessment of coronary narrow- 
ing on cineangiograms is associated with substantial inter- 
observer and intraobserver variability. Although indepen- 
dent quantitative angiographic techniques have become the 
gold standard for evaluating coronary obstructions, detelmi- 
nation of coronary aarroGng by caliper techniques i a 
readily available t chnique that correlates closely with com- 
puter quantitative methods for assessing percent stenosis 
(81). For the purpose of this report, a significant s enosis 
defined as one that results in a 50% reduction i  coronary 
diameter as determined bycaliper method or other quanti- 
tative angiographic te hnique. 
After a decade of experience, it is now reasonable to
expect of any angioplasty program an overall initial success 
rate of 290% for single lesion dilations. In addition to 
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a 
raphic ~~ara~te~5t~~§ of 
Patient-related factors 
success relates to certain 
nder, but clinical 
risk for the angiopiasty procedure are age <70 years, male 
gender, single-vessel and single-lesion coronary artery dis- 
ease, no history of congestive heart failure, left ventricular 
ejection fraction >40%, stable angina, and <9 
coronary stenosis (3,34,39,82-85). Type A core 
ses are discrete (5 10 mm in length) and concentric, and have 
accessibility; location in a 
; smoothness of contour; little 
uce of total occlusion, ostial 
location, major side branch involvement, or thro 
21. 
e. Features associated with in- 
advanced age, female gender, 
CA, diabetes melhtus, history 
of congestive heart failure, degree of left ventricular dys- 
function, left main equivalent coronary disease, inadequate 
antiplatelet therapy, unstable angina pectoris, PICA imme- 
diately following thrornbolytic therapy, and PEA at the 
time of initial catheterization forunstable angina pectoris 
(82-91). Lesion-specific variables include stenoses 290% in 
severity, stenosis bend angulation >45”, excessive proximal 
vessel tortuosity, intraluminal thrambus, and type B or C 
characteristics as enumerated in Table 2. Although many 
experienced operators, using both conventional nd newer 
technologies, have success rates of ~90% for PICA in 
lesions with type B or C characteristics (92-S), an important 
note of caution has been sounded regarding the interpreta- 
tion and implications ofsuch data, particularly as applied to 
the evaluation of newer technologies (93). Chronic total 
occlusions are the most significant predictor of procedural 
failure but usualslly donot pose a high risk to the patient. 
pt vessel chide. Although the correlates ofproce- 
dural complications noted above may serve to stratify 
groups of patients according to anticipated risk, they gener- 
ally have a low positive and negative p-edictive value. 
!k 2. Chamcaet-ishics of Type A, 
Lesion-Specific Charactetistics 
T A l&Or& 
Crete (8en mm) 
Concentric 
Readily accessible 
Nonangulated segment (=c45”) 
Smooth Cc9nmf 
Little oh no calcification 
Less than totally occlusive 
Not osIial in location 
No major side branch involvement 
Absence of thmrobus 
T lesions @I rately c~~~~~x)* 
lar (lengtth to 20 mm) 
Eccentric 
Moderate tortuosity of proximal segment 
Moderately angulatcd segment (>45”, -C 
h-regular contour 
Moderate or heavy calcification 
Total occlusions <3 ino old 
Ostid in location 
Bifurcation lesions requiring double guide wires 
Some thrombus present 
T lesions (severely comples) 
se (length >2 cm) 
Excessive tortuosity of proximal 
Extremely angulated segments > 
Total occlusions >3 mo old and/or bridging collaterals 
Inability to protect major side branches 
Degenerated vein grafts with friabk !esions 
*Although the risk of abrupt vessel c!osure may be moderately high ulitk 
Type B lesions. the likelihood of a major complication may be low in certain 
instances uch as in the dilation of total occlusions <3 mo old or when 
abundant collateral cbannek supply the distal vessel. 
vessel closure durin 
res and is largely 21 
tivariate analyses have identified branch vessel ocation, 
lesion length >I0 mm, right coronary artery stenosis, and 
coronary thrombus score as independent preprocedurat pre- 
dictors of abrupt vessel closure (97). Thrombus cores are 
determined by adding up the number of angiographic fea- 
tures (haziness, contrast ain, filling defect) hat suggest the 
presence of thrombus. Clinical and an@ographic variables 
associated with abrupt coronary artery occlusion are sum- 
marized in Table 3. Recent data have suggested that the 
presence ofthrombas i the most significant factor associ- 
ated with untoward events during PTCA (84,921. 
se. Certain variables may be use 
tar collapse if abrupt vessel closure c 
(83,&4,96). A composite four-variabl 
spectively validated to be both sen 
predicting cardiovascular collapse if
I) percentage of myocardium atrisk, 2) pre- 
diameter stenosis, 3) multivessel coronary artery disease, 
and 4) diEuse disease inthe dilated segment (%I. This index 
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Table 3. Factors Predictive of Abrupt Vessd closure 
Rep~Ure 
Clinical factors 
Female gender 
Unstable angina 
Insulin-dependent iabetes mellitus 
Inadequate ntiplatelet therapy 
Angiographic fa tors 
Intracoronary thrombus 
290% stenosis 
Stenosis length 2or more luminal diameters 
Stenosis atbranch point 
Stenosis on bend (~45”) 
Right coronary artery stenosis 
Postprocedure 
lntimal dissection > 10 mm 
Residual stenosis >50% 
Transient in-lab closure 
Residual transstenotic gradient 220 mm Hg 
proved highly sensitive and specific when prospectively 
compared with previously described risk factors uch as 
MO% viable myocardium at risk and left ventricular ejection 
fraction of ~25%. Similarly, a myocardial jeopardy score 
has been devised to help determine the degree of viabIe 
myocardium atrisk for ischemic dysfunction (98,99). This 
score divides the coronary tree into six segments and assigns 
two points to coronary segments subtended by stenoses of
275% severity. Added weight is given to the left anterior 
descending coronary distribution, which comprises three 
segments (Figure). Patients with higher preprocedural jeop- 
ardy scores hav:: a greater likelihood of cardiovascular 
collapse should abrupt vessel closure occur (84). 
Risk of death. The clinical varial:ies associated with 
increased mortality are identified as advanced age, female 
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gender, diabetes, prior myocardiai infarction, multivessel 
disease, left main or equivalent coronary disease, a large 
area of myocardium atrisk, impairment of left ventricular 
function, and collateral vessels upplying significant areas of 
myocardium that originate distal to the segment tobe dilated 
(41,82-84,100,101). Recent data have shown that the in- 
creased mortality among women undergoing angioplasty, 
compared with men, is associated with older age, more 
clinical heart failure, and unstable angina. Despite having 
more hypertension a d diabetes, the extent of coronary 
artery disease inwomen undergoing angiopiasty is no greater 
than that among men (102,103). Death is directly related to 
the occurrence of coronary artery occlusion and is most 
frequently due to left ventricular failure (84). Left ventricular 
failure was independently correlated with the coronary ar- 
tery jeopardy score, female gender, and PTCA of a proximal 
right coronary artery stenosis. Factors associated with death 
following angioplasty are listed in Table 4. 
These clinical variables can be assessed before the per- 
formance ofPTCA and should help to determine procedural 
risk, particularly the risk of abrupt vessel closure and 
cardiovascular collapse. Patients having ahigher-risk profile 
may be candidates for alternative therapies, particularly 
coronary bypass urgery, or for more formalized surgical 
standby or periprocedural hemodynamic support. 
Angioplasty at the Time of Initial 
Cardiac Catheterization 
The selection ofpatients for angioplasty demands careful 
review of the clinical and anatomic features of each case. 
This is optimally done after diagnostic cardiac atheteriza- 
tion and review of the cineangiograms. This process, how- 
ever, obviously subjects the patient o a repeat invasive 
B 
Diagrammatic illustration of coro- 
nary artery jeopardy score seg- 
ments for patients with either 
right coronary (panel A) or left 
coronary (panel 5) dominance. 
Coronary segments subtended by 
stenoses of 275% severity are as- 
signed two points. The occur- 
rence of cardiogenic shock after 
abrupt vessel closure is more fre- 
quently observed with jeopardy 
scores of ZSl in men or 23.5 in 
wemen. Diag or DIAG indicates 
diagonal branch; LAD, left ante- 
rior descending: LCx, left circum- 
flex: EM, left main coronary ar- 
tery; MARC or OM, obtuse 
marginal branch; PDA, posterior 
descending coronary artery; PL, 
posterolateral branch; RCA, right 
coronary artery; Sept or SEPT, 
septal branch. (Adapted from Ref- 
erences 84 and 99 with permis- 
sion.) 
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Age >65 years 
Unstable angina 
Congestive heart failure 
failure 
eb3rs 
Left main CGiOX3lJJ disease 
Three-vessel disease 
Left vefihdar ejection fraction < 0.30 
Risk index* 
Myocardial jeopardy score 
Proximal right coronary stenosis 
C~Z!atera!s ziginate from dilated vessel 
*See reference 96. 
procedure with its in erent risk arrd recog 
lengthens ~os~ita~~~atio~~ and addsto t e direct and indirect 
costs involved. 
A staged approach to coronary a~gio~~asty fter cardiac 
catheterization has certain advaratages: it allows more time 
to plan the dilation strategy, to have ~~rns~~~~~~~ 
cdeagues, to have more extensive discussion with the 
by IS%, arrd reduces radiation e 
ing the safety of the procedure 
Combined a~giogra~~y and
for three subsets of patients: I) patients wit 
out additional comphcatious if the lesions are clearly identi- 
fied at aogiography with high-quality image systems and the 
patient is well informed and prepared before the procedure 
(109). In ah cases, however, any decision regarding PEA 
should be delayed if there is any question about he need for, 
the suitability of, or the preference for RCA as opposed to 
medical or surgical treatment. 
nary a~~o~~asty, a tention isdi- 
rected to mnitoring for evidence of recurrent ischemia, to 
ensuring appropriate h mostasls at the site of catheter inser- 
tion, and to detecting and preventing contrast-induced r nal 
ending on the patient, advice should idude 
it was positive preangioplasty) andcan be use 
advice rr exercise and 
test 3 to 6 months afte 
restenosis and, in asymptomatic patients, may be somewhat 
more specific than exercise stress electrocardiography (I 12
114). 
Some 12% to 20% of asymptomatic patients will have 
significant angiographic restenosis 6 morkths after 
many cases, this can be detected by noninvasive 
(115,186). ver, if a patient has rro artgin 
negative st CC, or negative r s 
sciatigrapby, the probability of a sr 
approximately 55 (115, I 16). In the 
modest reversibk defect on stres 
may not justify repeat angioplasty. CSoZarY a@O@VhY 
may be indicated in some patients without evidence Of 
myocardial &hernia because of special employment or 
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occupational requirements or other factors judged to be 
important by their physician. 
If significant clinical restenosis i  identified at any time 
after PTCA, indications for repeat PTCA should follow the 
general indications as outlined in “Indications for Angio- 
plasty.” If restenosis has not occurred by 6 months after 
PTCA, it is unusual for it to develop later; subsequent 
clinical evidence of myocardial ischemia is usually associ- 
ated with progression f disease lsewhere inthe coronary 
tree (117). 
Restenosis 
Although the initial outcome for coronary angioplasty 
procedures has improved over the past 35 years, the inci- 
dence of coronary restenosis after dilation has remained 
unchanged at30% to 40% and is perhaps higher in certain 
complex lesions (110,118,119). Therate of restenosis n
native arteries depends partly on its definition. Of the 
different restenosis criteria proposed, a HO% diameter 
stenosis at follow-up angiography is the most frequently 
used (120). Investigators u ing quantitative angiographic 
techniques have proposed using the change in minimal 
lumen diameter from that after PTCA to that at follow-up, 
normalized for the reference vessel diameter ( elative loss) 
(121-123). Ultimately it is the minimal lumen diameter ofthe 
residual stenosis after healing related to the vessel’s normal 
size that is important. A dichotomous variable such as HO% 
stenosis at follow-up may work well in clinical practice, but 
it is to be noted that all dilated arteries undergo some 
healing. For this reason, the continuous variables ofminimal 
lumen diameter or percent diameter stenosis at follow-up 
best describe restenosis n large patient populations. Ac- 
cordingly, they should be used in clinical trials aimed at 
altering the restenosis process. 
The pathogenesis of the restenotic process ubsequent to 
mechanical injury is incompletely understood but appears 
multifactorial. The principal factors include elastic recoil, 
organization f thrombus adherent to the site of arterial 
injury, and growth factor stimulation of smooth muscle 
proliferation (124-126). 
The value of symptoms for detecting restenosis has 
varied widely among studies, although on average, 60% to 
70% of patients with recurrent angina within 5 months of 
PICA have restenosis and 10% to 20% of those without 
recurrent symptoms have restenosis (110). 
Patient-related factors that appear to predispose the pa- 
tient o restenosis include male gender, continued smoking 
after angioplasty, diabetes, elevated blood insulin levels, 
absence of previous myocardial infarction, and unstable 
angina Ill9,126,127), although one recent analysis has ques- 
tioned fhe relationship of smoking to restenosis (128). An- 
giographic factors related to restenosis include angioplasty 
of the proximal left anterior descending coronary, the pres- 
ence of chronic total coronary occlusion, stenoses at the 
origin of vessels, branch vessel stenoses, long lesions, the 
presence ofthrombus, and stenoses involving the proximal 
and middle regions of saphenous vein bypass grafts 
(110,118,119,126). Datafrom one recent report, 
suggest that, at least with respect to the rate of 
observed indiverse segments ofthe coronary tree, resteno- 
sis is an ubiquitous phenomeno without predilection for a 
particular site or segment (123). cedural vaaiables related 
to restenosis nclude postangioplasty residual stenosis of 
~30% and pressure gradient of >15 mm Mg. Extensive 
coronary dissection appears to be associated with a high rate 
en correlated with an increased 
incidence of restenosis include age, functional cIas 
of previous myocardial nfarction, hypertension, se 
lesterol, presence of calcification at the site of 
morphological features of the lesion, inflation pressure, an 
medications taken at time of discharge. 
Patients who develop clinical or angiographic evidence of 
restenosis n native coronary arteries u
second ilation proce ure. For repeat ang 
mary success rate ap ars higher than fo 
dure with a relatively ow incidence ofmyocardial infarction 
or need for emergency oronary artery bypass urgery. The 
rate of recurrent restenosis, however, is somewhat higher 
than the rate of restenosis after the initial 
Pncomplete Revaseularization 
As coronary angioplasty is being used in more complex 
clinical and pathoanatomic s tuations, the couczrn arises 
that patients are being aubjectcd to incomplete r vascular- 
ization or less-than-optimal correction or’their pathophysio- 
logical state. The surgical experience is convincing that 
complete r vascularization leads to superior results in terms 
of relief of angina, less myocardial ischemia, better hemo- 
dynamic performance onpostoperative stress testing, and 
freedom from subsequent coronary events including reoper- 
ation, myocardial infarction, and death (130). 
Incomplete or partial revascularization s often a pre- 
planned therapeutic strategy in patients undergoing angio- 
plasty because ofmorphological f ctors precluding success- 
ful dilation of all lesions leg, chronic total occlusions, mild 
lesions) (92,131). Although early graft closure after bypass 
surgery also converts complete revascularization t  partial 
revascularization, this phenomenon is less common than 
restenosis after angioplasty. Some studies have suggested 
that incomplete revascularization n patients undergoing 
angioplasty may also unfavorably influence long-tern sur- 
vival (23,31,132). 
Partial revascularization after coronary angioplasty is an 
inherent limitation of the procedure and can be expected to 
occur more frequently in patients undergoing multivessel 
angioplasty. Frequently, especially inelderly patients, only 
one targeted lesion thought o be responsible for the pa- 
tient’s ymptoms i  dilated to reduce the risk of the proce- 
dure, Nonetheless, many patients experience r lief of symp- 
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al revasculatiza- 
aits the outcome of ~mgoing c
CA is more likely the result of a strat 
(nss). 
cedure” compared with the ~j~elib~~d of failure and the risk 
vessel closure, morbidity, mortal- 
ritizing i~d~cat~o~s for an
the c~mm~ttec wa by the 
ors fav 
ful dilation; 2) factors associated with and consequences o 
abrupt vessel closure; 3) ~~c~m~~ctc revascular- 
ure of the procedure 
appropriate w ighting and integration f important variables 
to formulate likelihood estimates (hush, moderate, orlow) of 
the success of any given procedure according to the likeli- 
hood of a successful dilation (see Tables 2 and 4); the 
livelihood of abrupt vessel closure, with subsequent morbid- 
ity and mortality (Table 3); the likelihood of restenosis; and 
the long-term prognosi 3.
Although operator experience and individual patient 
characteristics are important factors relating to outcome, 
both procedural success and abrupt vessel closure are in 
large part determined by specific patient characteristics and 
lesion morphology (139,140). It must be recognized that his 
aspect of cardiovascular care is runcterg&g considerable 
growth and development and that frequent updates may be 
required as new insights are gained. Currently, the foBowing 
classifications are used to indicate the degree of consensus of 
the committee members and the reviewing bodies for spe- 
cific applications of angioplasty: 
*A succes&l procedure is defined as one in which a ~20% change in 
luminal diameter isachieved with the final diameter stenosis -=3Q%, without 
the occurrence of death, acute myocardial infarction, or bypass operation 
during hospitalization. 
of viable myocardiu 
bit studies, or both, or 
noncardiac surgery, such 
as repair of an aortic aneurysm, iliofemorzd bypass, or 
carotid artery surgery, if angina is present or then is 
objective vidence of ischemia as described above. 
AU of these patients ho&! have a lesion or lesions 
associated with a high likelih od of successful dilation, and 
be at Isw risk for morbidity and mortality. 
lesion in a major epicardial rtery that subtends at least a 
moderate-sized mz of viable myocardium and 
iFor the purpo=~ or:?& report. a significant s enosis defined as one that 
results in a ~-50% ieduction in curona~, diameter as determined by caliper 
method. 
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1. show objective vidence of myocardial ischemia* dur- 
ing laboratory testing and 
a. have at least a moderate likelihood of successful 
dilation, and 
b. have a low risk of abrupt vessel closure, and 
c. are at low risk for morbidity and mortality. 
Class III (milcl or no symptoms, single-vessel comq -1 
This category applies to all other patients with single- 
vessel disease and mild or no symp?oms who do not fulfill the 
preceding criteria for Class I or Class II. It includes, for 
example, patients who 
I. have only a small area of viable myocardium atrisk, or 
2. do not manifest evidence of myocardial ischemia dur- 
ing laboratory testing, or 
3. have borderline l sions (50% to 60% diameter reduc- 
tion) and no inducible ischemia, or 
4. are at moderate orhigh risk for morbidity and mortal- 
ity. 
In some patients, circumstance of occupation oremploy- 
ment may result in a Class II indication being viewed as a 
Class 1 category. Such patients would include those whose 
occupation i volves the safety of others (eg, airline pilots, 
bus drivers, truck drivers, and air-t&c controllers) and 
those in certain occupations that frequently require sudden 
vigorous activity (eg, firefighters, police officers, and ath- 
letes). However, Class III indications for asymptomatic or 
mildly symptomatic individuals with single-vessel disease 
pertain to a risk profile that precludes the patient’s belonging 
in Class I or Class II. 
Symptomatic patients with angina pectoris (functionaf 
Classes II to IV, unstable angina) with medical therapy and 
single4essel disease 
Class I
This category applies to patients who have a significant 
lesion in a major epicardial rtery that subtends at least a 
moderate-sized area of viable myocardium and who 
1. show evidence of myocardial ischemia while on medi- 
cal therapy (including ECG monitoring atrest), or 
2. have angina pectoris that is inadequately responsive? 
to medical treatment, or
3. are intolerant ofmedical therapy because ofuncontrol- 
lable side effects. 
*Evidence ofmyocardial ischemia during laboratory testing is taken to 
mean exercise-induced ischemia (with or without exercise-induced angina 
pectoris) manifested by 4 mm of ischemic ST segment depression r one or 
more stress-induced r versible nuclear perfusion defects and/or exercise- 
induced reduction in the ejection fraction and/or wall motion abnormalities on 
radionuclide v ntriculographic or stress echocardiographic studies. 
YInadequately responsive” asused in this report means that patient and 
physician gree that an&a significantly interferes with the patient’s occupa- 
tion or ability to perform usual activities. 
All of these patients hould have at least a moderate 
likelihood of successful dilation and be at low or moderate 
risk for morbidity and mortality. 
lies to patients wh 
lesion in a major epicardial rtery that subtends at least a 
moderate-sizeci area of viable myocardium and who 
1. show evidence of myocardial ischemia during labora- 
tory testing and 
a. have one or more complex (type 
ogy) lesions in the same vessel or its branches, or 
b. are at moderate risk for morbidity or 
2. have disabling symptoms and a small area of viable 
myocardium atrisk, and 
a. at least a moderate likelihood of successful dilation 
and 
b. are at low risk for morbidity and mortality, or 
3. have at least moderately severe angina on medical 
therapy with equivocal or nondiagnostic evidence of 
myocardial ischemia on laboratory testing and who 
prefer treatment with coronary angioplasty to medical 
therapy, and 
a. have at least a moderate likelihood of successful 
dilation, and 
b. are at low risk for morbidity and mortality. 
tomatic, single-vessel coronary disease) 
This category applies to all other symptomatic patients 
with single-vessel disease who do not fulfill the preceding 
criteria for Class I or Class II. It includes, for example, 
patients who 
1. 
2. 
3. 
4. 
5. 
have no or only a small area of viable myocardium at
risk in the absence ofdisabling symptoms, or
have clinical symptoms not likely to be indicative of 
ischemia, or 
have a very low likelihood of successful dilatation, or 
are at high risk for morbidity and mortality, or 
have no symptoms orobjective vidence ofmyocardial 
ischemia during high-level stress testing (212 METS). 
Patients with single-vessel disease who have significant 
symptoms constitute one of the largest groups of patients 
undergoing angioplasty. However, the generally excellent 
prognosis for patients with single-vessel disease should be a 
paramount consideration before an interventional procedure 
is under taken in these patients. It is imperative that here be 
some assurance that he significant symptoms are indeed ue 
to the coronary lesion proposed for dilation. Although 
significant symptoms may justify a lower tolerance for the 
risk of abrupt vessel closure or subsequent restenosis, one 
cannot compromise on the risk for significant mortality or 
morbidity. In view of evidence that angina can diminish, or 
even disappear, in many patients with occlusive coronary 
disease, specially those with single-vessel disease, patients 
I. who are similar to patients inClass I but 
1. have a moder;a~e-sized area of viable m 
risk, or 
b. have objective vidence of yscardial ischemia 
during laboratory testing, or 
2. who have sign&ant sions in two or more major 
epicardial rteries, ea of which subtends at least a 
ma&rare-sized area of viable myocardium, or
3. who have a subtotally occhrded vessel requiring angio- 
plasty wherein t1.e development of total occlusion of 
the vessel would result in severe hemodynamic col- 
lapse due to left ventricular dysfunction. 
All of these patients hould show evidence of myocardial 
ischemia during laboratory testing, have Iesions with at least 
a moderate likelihood of successful dilation, the successful 
dilation of which would provide relief to all major egions of 
ischemia, nd be at low or moderate risk for morbidity and 
mortality. 
CBm d to IQ9 s %ms, 
This category applies to all other patients with multives- 
se1 disease and mild or no symptoms who do not fullill the 
above criteria for Class I or Class II. It includes, for 
example, patients who 
at low risk for morb 
1. are similar to patients in Class I but who are at 
moderate risk for morbidity and mcrtalitv or 
2. have angina pectoris but do not ne 
jective vidence ofmyocardial isch 
tory testing. 
All of these patients hould have lesion morphology 
associated with a high rate of Juccess 
would provide relief of all major egions of ischemia, nd be 
at moderate risk for morbidity and mortality. 
atients in this category also are those who 
3. 
4. 
have disabling angina that has proved inadequately 
responsive tomedical therapy and 
a. are considered poor candidates for surgery because 
of advanced physiologic age or coexisting medical 
disorders, and 
b. have lesions with at Least amoderate Ii 
successful dilation, and 
c. are at moderate risk for morbidity and mortality, or 
have a snbtotally occluded vessel reqluiring angioplasty 
and the total occlusion of the vessel wonld result in 
severe hemsdynamic collapse due to left ventricular 
dysfunction. 
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Qass III (symptomatic, multivessel coronary disease) 
This category applies to all other symptomatic patients 
with multivessel disease who do not fi~lfill the preceding 
criteria in Class I or Class II. It includes, for example, 
patients who 
1. have only a small area of myocardium atrisk in the 
absence ofdisabling symptoms, or
2. have lesion morphology with a low likelihood of SUC- 
cessfd dilation and subtending moderate orlarge areas 
of viable myocardium, or
3. are at high risk for morbidity or mortality, or both. 
It is to be stressed that risk assessment is different in 
patients with multivessel disease than in those with single- 
vessel disease. In the former group there ideally should be 
the opportunity for anatomically complete r vascularization, 
although adequate functional revascularization can be 
achieved without necessarily being anatomically complete. 
In every instance the goal is to achieve relief of ischemia at 
a risk acceptable for the procedure. In estimating this risk in 
multivessel disease it is imperative that each lesion be 
considered in the context of all other lesions present. Some 
assessment must hen be made of the likely consequences 
should any one of the attempted dilations fail and result in 
abrupt vessel closure, For example, there is an increased 
risk in dilating aleft coronary artery lesion if it jeopardizes 
the entire collateral blood supply to a large area of viable 
myocardium in the distribution ofa totally occluded, nondi- 
latable, dominant right coronary artery (141). On occasion 
exceptions to these guidelines may be made based on 
operator judgment, experience, and the patient’s desires, 
particularly in some patients at higher isk for a procedural 
complication. 
Direct Immediate Curonary Angioplasty for 
Evolving Acute Myocardial Infurction 
ehm I 
This category applies to the dilation of a significant lesion 
in the infarct-related artery only in patients who can be 
managed in the appropriate laborntor,: setting and who 
are within 0 to 6 hours of the onset of a myocardial 
infarction (the procedure is used as an alternative to
thrombolytic herapy), 
are within 6 to 12 hours of the onset of a myocardial 
infarction but who have continued symptoms ofongo- 
ing myocardial ischemia, or 
are in cardiogenic shock with or without previous 
thrombolytic herapy and within 12 hours of the onset 
of symptoms. 
chss II 
This category applies to patients who 
1. are within 6 to 12 hours of the onset of an acute 
myocardial infarction and have no symptoms ofmyo- 
2. 
3. 
cardial ischemia but have a large area of myocardi~m at 
jeopardy and/or are in a higher-risk clinical category 
are within 12 to 24 hours of the onset of an acute 
myocardial infarction but who have continued symp- 
toms of ongoing myocardial ischemia, or 
have received thrombolytic therapy and have continu- 
ing or recurrent symptoms of active myocardial isch- 
emia. 
Class 
This category applies to 
angioplasty of a no i~fa~~t~~elated artery at the time 
of acute myocardial infarction, 
patients who are more than 12 hours after the onset of 
acute myocardial infarction at the time of admission 
and who have no symptoms ofmyocardial ischemia, or 
patients who have had successful thrombolytic herapy 
within the past 24 hours and have no symptoms of 
myocardial iscbemia. 
The role of direct angioplasty in the management of 
patients during the course of acute myocardial infarction is 
currently the subject of intense investigation (142). Two 
major factors leading to the current interest in “primary” 
angioplasty in acute myocardial infarction patients without 
preceding fibrinolytic therapy are 1) the realization that 
<25% of acute myocardial infarction patients in the United 
States receive fibrinolytic therapy and 2) the findings of three 
large clinical trials that bleeding complications were seen 
more frequently when PTCA was preceded by intravenous 
thrombolytic therapy with tissue plasminogen activator 
(143-145). Not only were transfusion rates after immediate 
angioplasty two to three times those reported after deferred 
angioplasty, overall mortality and left ventricular function 
were not significantly improved by the combination strategy 
(146). A number of single-center, nonrandomized, noncon- 
trolled studies indicate that the procedure iseffective as a 
primary means of establishing reperfusion i  the early hours 
of an evolving cnyocardial nfarction (147-M). The proce- 
dure is associated with the relief of acute symptoms and 
associated with acceptable mortality rates when dilation has 
been successful. 
In addition, there are observational data from one large 
registry study (152) and several randomized clinical trials 
(153-M) comparing direct angioplasty with intravenous 
thrombolytic therapy in patients with acute myocardial 
infarction. These data suggest that direct PTCA is at least as 
efficacious a thrombolytic herapy and, in certain subsets of 
patients, may even be superior in terms of recurrent isch- 
emit events, cost reduction, and short-term survival. Al- 
though these observations have major implications for the 
large cohort of acute myocardial infarction patients who are 
ineligible for thrombolytic therapy, there are substantial 
differences in terms of mortality risk between a population rf 
acute myocardial infarction patients who are eligible and 
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lesion(s) in patients who 
have recm-rent episodes of ischemi 
ularly if accompanied byelectroca 
(postinfarction a gina), or 
show objective vidence ofmyoca 
laboratory testing performed before discharge from the 
hospital, or 
have recilrrent sustained ventriclalar tachycardia or
ventricular ~b~~Iatio~~ r oth, while receiving iaten- 
sive medical therapy. 
All of these patients should have one or more lesions that 
predict a high (SO%) success rate and be at low risk for 
morbidity and mortality. 
This category applies to the dilatiom ofsignificant lesions 
in patients who 
II. are similar to patients ia Class 1 but 
a, have more complex lesions with at least a moderate 
likelihood of successful dtiation, or 
b. undergo multivessel angiopkty, or 
c. are at moderate risk for morbidity or mortality or
both: or 
2. have survived cardiogefic shock in the period before 
discharge or 
he selection of patients for coronary angio 
rocedures in the recovery 
olysis (143-145). Studies have also shown that 
of angioplasty in acute patients. 
continue to generate new observations that 
ing hypotheses and raise questions with far= 
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implications, An example is the issue and uncertainty sur- 
rounding the value of an open infarct-related artery at the 
time of discharge from the hospital after infarction in the 
absence of demonstrated myocardial ischemia (171-173). 
Similarly, data re now emerging to suggest that angioplasty 
of significant residual lesions in infarct-related arteries in 
some subsets of patients without symptoms but with objec- 
tive evidence ofischemia after thrombolytic herapy may be 
harmful (174). It should be apparent that such subset analy- 
ses produce xploratory esults that provide clear direction 
for new lines of investigation but certainly do not establish 
firm guidelines for clinical practice. 
It is in this context that hese guidelines are promulgated, 
with the conviction that he prudent physician will have no 
dificulty in identifying those areas about which firm clinical 
opinion is established and those that represent ew frontiers 
of practice that must await confirmation from additional 
clinical investigation. 
This ctassification s adopted from the grading ofangina of effort by the 
Canadian Cardiovascular Society (175). 
I. Angina is not caused by ordinary physical ctivity, such as walking and 
climbing stairs, Angina is experienced with strenuous orrapid or pro- 
longed exertion at work or recreation. 
II. There is slight limitation ofordinary activity, such as walking or climbing 
stairs rapidly; walking uphill; walking or stair-climbing after meals; or 
walking more than two blocks on the level and climbing more than one 
i&$t of ordinary stairs at a normal pace and in normal conditions; or
angina is experienced in cold, in wind, during emotional stress, or only 
during the few hours after awakening, 
III. There is marked limitation ofordiuary physical ctivity, such as walking 
one to two blocks on the level and climbing one flight of stairs in normal 
conditions and at a normal pace. 
IV. There is an inability to carry on any physical ctivity without discomfort; 
angina! syn.lrome may be present at rest. 
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